Chemogenetic Activation of Specific GPCR Signaling Pathways to Identify Novel Targets for Antidiabetic Drugs
Time: 12:00 pm
day: Day One Track A AM
Details:
- Leveraging designer GPCRs known as DREADDs (Designer Receptors Exclusively Activated by a Designer Drug) to selectively activate distinct classes of heterotrimeric G proteins
- Using DREADDs to identify novel cellular targets for the treatment of major metabolic disorders
- Optimizing DREADD technology to identify distinct GPCR signaling pathways involved in type 2 diabetes and obesity in vivo
